Active Pharmaceutical Ingredient CDMO Market Size, Share & Trends Analysis Report By Product, By Synthesis, By Drug, By Application, By Workflow, By Region, And Segment Forecasts, 2024 - 2030

Research Methodology

A three-pronged approach was followed for deducing the active pharmaceutical ingredient cdmo market estimates and forecasts. The process has three steps: information procurement, analysis, and validation. The whole process is cyclical, and steps repeat until the estimates are validated. The three steps are explained in detail below:

Information procurement: Information procurement is one of the most extensive and important stages in our research process, and quality data is critical for accurate analysis. We followed a multi-channel data collection process for active pharmaceutical ingredient cdmo market to gather the most reliable and current information possible.

• We buy access to paid databases such as Hoover’s and Factiva for company financials, industry information, white papers, industry journals, SME journals, and more.
• We tap into Grand View’s proprietary database of data points and insights from active and archived monitoring and reporting.
• We conduct primary research with industry experts through questionnaires and one-on-one phone interviews.
• We pull from reliable secondary sources such as white papers and government statistics, published by organizations like WHO, NGOs, World Bank, etc., Key Opinion Leaders (KoL) publications, company filings, investor documents, and more.
• We purchase and review investor analyst reports, broker reports, academic commentary, government quotes, and wealth management publications for insightful third-party perspectives.

Analysis: We mine the data collected to establish baselines for forecasting, identify trends and opportunities, gain insight into consumer demographics and drivers, and so much more. We utilized different methods of active pharmaceutical ingredient cdmo market data depending on the type of information we’re trying to uncover in our research.

• Market Research Efforts: Bottom-up Approach for estimating and forecasting demand size and opportunity, top-down Approach for new product forecasting and penetration, and combined approach of both Bottom-up and Top-down for full coverage analysis.

• Value-Chain-Based Sizing & Forecasting: Supply-side estimates for understanding potential revenue through competitive benchmarking, forecasting, and penetration modeling.

• Demand-side estimates for identifying parent and ancillary markets, segment modeling, and heuristic forecasting.

• Qualitative Functional Deployment (QFD) Modelling for market share assessment.

Market formulation and validation: We mine the data collected to establish baselines for forecasting, identify trends and opportunities, gain insight into consumer demographics and drivers, and so much more. We utilize different methods of data analysis depending on the type of information we’re trying to uncover in our research.

• Market Formulation: This step involves the finalization of market numbers. This step on an internal level is designed to manage outputs from the Data Analysis step.

• Data Normalization: The final market estimates and forecasts are then aligned and sent to industry experts, in-panel quality control managers for validation.

• This step also entails the finalization of the report scope and data representation pattern.

• Validation: The process entails multiple levels of validation. All these steps run in parallel, and the study is forwarded for publishing only if all three levels render validated results.

Active Pharmaceutical Ingredient CDMO Market Categorization:

The active pharmaceutical ingredient cdmo market was categorized into four segments, namely product (Traditional Active Pharmaceutical Ingredient (Traditional API), Highly Potent Active Pharmaceutical Ingredient (HP-API), Antibody Drug Conjugate (ADC)), synthesis (Synthetic, Biotech), drug (Innovative, Generics), workflow (Clinical, Commercial), application (Oncology, Hormonal, Cardiovascular disease, Diabetes), and regions (North America, Europe, Asia Pacific, Latin America, Middle East & Africa).

Segment Market Methodology:

The active pharmaceutical ingredient cdmo market was segmented into product, synthesis, drug, workflow, application, and regions. The demand at a segment level was deduced using a funnel method. Concepts like the TAM, SAM, SOM, etc., were put into practice to understand the demand. We at GVR deploy three methods to deduce market estimates and determine forecasts. These methods are explained below:

Market research approaches: Bottom-up

• Demand estimation of each product across countries/regions summed up to from the total market.

• Variable analysis for demand forecast.

• Demand estimation via analyzing paid database, and company financials either via annual reports or paid database.

• Primary interviews for data revalidation and insight collection.

Market research approaches: Top-down

• Used extensively for new product forecasting or analyzing penetration levels.

• Tool used invoice product flow and penetration models Use of regression multi-variant analysis for forecasting Involves extensive use of paid and public databases.

• Primary interviews and vendor-based primary research for variable impact analysis.

Market research approaches: Combined

• This is the most common method. We apply concepts from both the top-down and bottom-up approaches to arrive at a viable conclusion.

Regional Market Methodology:

The active pharmaceutical ingredient cdmo market was analyzed at a regional level. The globe was divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, keeping in focus variables like consumption patterns, export-import regulations, consumer expectations, etc. These regions were further divided into twenty-five countries, namely, the U.S.; Canada; U.K.; Germany; France; Italy; Spain; Denmark; Sweden; Norway; Japan; China; India; Australia; Thailand; South Korea; Brazil; Mexico; Argentina; Colombia; Chile; South Africa; Saudi Arabia; UAE; Kuwait

All three above-mentioned market research methodologies were applied to arrive at regional-level conclusions. The regions were then summed up to form the global market.

Active pharmaceutical ingredient cdmo market companies & financials:

The active pharmaceutical ingredient cdmo market was analyzed via companies operating in the sector. Analyzing these companies and cross-referencing them to the demand equation helped us validate our assumptions and conclusions. Key market players analyzed include:

• Cambrex Corporation - Cambrex Corporation is a provider of healthcare products and services. The company specializes in Active Pharmaceutical Ingredients (APIs), advanced intermediates, and enhanced drug delivery products for branded & generic pharmaceuticals. The company has production sites in the U.S., Europe, and India, with global sales.

• Recipharm AB - Recipharm AB is a global pharmaceutical Contract Development and Manufacturing Organization (CDMO). The company offers development and manufacturing services, including a wide variety of drug dosage forms, and inhalation products & devices.

• THERMO FISCHER SCIENTIFIC INC. (PATHEON) - Patheon was acquired by SE Thermo Fischer in 2017. The company offers pharmaceutical development, biologic manufacturing, commercial manufacturing, API supply, softgels, and early development services. Patheon’s and Fisher Clinical Services were merged to undertake drug development, clinical trial logistics, and commercial manufacturing.

• Samsung Biologics - Samsung Biologics is a fully integrated CDMO that offers contract development, manufacturing, and laboratory testing services. It produces biopharmaceutical products for established brands, such as Bristol-Myers Squibb and Roche. It was founded by Samsung Electronics, Samsung Everland, Samsung C&T, and Quintiles Transnational.

• Lonza Group Ltd. - Lonza Group Ltd. is an international leader in life sciences. It is a preferred global partner for players in biotech, pharmaceutical, and specialty ingredients markets. Its pharma & biotech segment includes CDMO services for small molecules, mammalian & microbial, cell & gene technologies, and live biotherapeutics products.

• Catalent, Inc. - Catalent, Inc. provides advanced delivery technologies and development & manufacturing solutions for biologics, drugs, gene therapies, & consumer health products. The company operates through four reportable segments: clinical supply service, oral drug delivery, biologics & specialty drug delivery, and softgel technologies.

• Siegfried Holding AG - Siegfried Holding AG is an internationally recognized outsourcing partner that provides custom services to its customers. The company provides pharmaceutical industry partners with services such as development of drug substances & drug products, registration, manufacturing, packaging, and logistics. It also provides technology capabilities and services.

• Piramal Pharma Solutions - Piramal Pharma Solutions is a leading company in pharmaceutical, financial services, and real estate conglomerate divisions. It offers services for the drug lifecycle, ranging from drug R&D in commercial drug substances to product manufacture. It also provides contract manufacturing services for API, HPAPI, and a range of dosage forms.

• Boehringer Ingelheim - Boehringer Ingelheim is a family-owned biopharmaceutical, human health, and animal health company. The company manufactures and distributes vaccines, parasiticides, & therapeutics, as well as diagnostics & monitoring platforms. It provides contract development and manufacturing services for biopharmaceuticals to the pharmaceutical & biotechnology industries.

• CordenPharma International - CordenPharma International is a full-service partner in API CDMOs, drug products, and associated packaging services. It operates under four technology platforms: Peptides, Lipids & Carbohydrates, Injectables, Highly Potent & Oncology, Small Molecules.

Value chain-based sizing & forecasting

Supply Side Estimates

• Company revenue estimation via referring to annual reports, investor presentations, and Hoover’s.

• Segment revenue determination via variable analysis and penetration modeling.

• Competitive benchmarking to identify market leaders and their collective revenue shares.

• Forecasting via analyzing commercialization rates, pipelines, market initiatives, distribution networks, etc.

Demand side estimates

• Identifying parent markets and ancillary markets

• Segment penetration analysis to obtain pertinent

• revenue/volume

• Heuristic forecasting with the help of subject matter experts

• Forecasting via variable analysis

Active Pharmaceutical Ingredient CDMO Market Report Objectives:

• Understanding market dynamics (in terms of drivers, restraints, & opportunities) in the countries.

• Understanding trends & variables in the individual countries & their impact on growth and using analytical tools to provide high-level insights into the market dynamics and the associated growth pattern.

• Understanding market estimates and forecasts (with the base year as 2023, historic information from 2018 - 2022, and forecast from 2023 to 2030). Regional estimates & forecasts for each category are available and are summed up to form the global market estimates.

Active Pharmaceutical Ingredient CDMO Market Report Assumptions:

• The report provides market value for the base year 2023 and a yearly forecast till 2030 in terms of revenue/volume or both. The market for each of the segment outlooks has been provided on region & country basis for the above-mentioned forecast period.

• The key industry dynamics, major technological trends, and application markets are evaluated to understand their impact on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis.

• We have used the bottom-up approach for market sizing, analyzing key regional markets, dynamics, & trends for various products and end-users. The total market has been estimated by integrating the country markets.

• All market estimates and forecasts have been validated through primary interviews with the key industry participants.

• Inflation has not been accounted for to estimate and forecast the market.

• Numbers may not add up due to rounding off.

• Europe consists of EU-8, Central & Eastern Europe, along with the Commonwealth of Independent States (CIS).

• Asia Pacific includes South Asia, East Asia, Southeast Asia, and Oceania (Australia & New Zealand).

• Latin America includes Central American countries and the South American continent

• Middle East includes Western Asia (as assigned by the UN Statistics Division) and the African continent.

Primary Research

GVR strives to procure the latest and unique information for reports directly from industry experts, which gives it a competitive edge. Quality is of utmost importance to us, therefore every year we focus on increasing our experts’ panel. Primary interviews are one of the critical steps in identifying recent market trends and scenarios. This process enables us to justify and validate our market estimates and forecasts to our clients. With more than 8,000 reports in our database, we have connected with some key opinion leaders across various domains, including healthcare, technology, consumer goods, and the chemical sector. Our process starts with identifying the right platform for a particular type of report, i.e., emails, LinkedIn, seminars, or telephonic conversation, as every report is unique and requires a differentiated approach.

We send out questionnaires to different experts from various regions/ countries, which is dependent on the following factors:

• Report/Market scope: If the market study is global, we send questionnaires to industry experts across various regions, including North America, Europe, Asia Pacific, Latin America, and MEA.

• Market Penetration: If the market is driven by technological advancements, population density, disease prevalence, or other factors, we identify experts and send out questionnaires based on region or country dominance.

The time to start receiving responses from industry experts varies based on how niche or well-penetrated the market is. Our reports include a detailed chapter on the KoL opinion section, which helps our clients understand the perspective of experts already in the market space.